Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities

Area of Science:

• Neuroscience
• Pathology
• Molecular Biology

Background:

• Dystrophic neurites are a key pathological feature of Alzheimer's disease (AD), often found near amyloid plaques.
• Reticulon 3 (RTN3) has been identified as a protein accumulating within a specific subset of these dystrophic neurites, termed RTN3 immunoreactive dystrophic neurites (RIDNs).

Purpose of the Study:

• To investigate the role of Reticulon 3 (RTN3) accumulation in the formation of dystrophic neurites and its contribution to Alzheimer's disease (AD) pathogenesis.
• To explore the potential of targeting RTN3 aggregation as a therapeutic strategy for AD.

Main Methods:

• Immunohistochemistry and ultrastructural analysis were used to identify and characterize RIDNs in post-mortem human AD brains and in mouse models.
• Transgenic mouse models overexpressing RTN3 (Tg-RTN3) were generated to study the effects of elevated RTN3 levels on neuritic morphology and cognitive function.
• Spatial learning and memory, as well as synaptic plasticity, were assessed in Tg-RTN3 mice.

Main Results:

• RTN3 accumulates in dystrophic neurites (RIDNs) in conjunction with high-molecular-weight RTN3 aggregates in AD brains and mutant APP mouse models.
• Overexpression of RTN3 in Tg-RTN3 mice led to the development of RIDNs, initially in the hippocampus and later in cortical regions.
• The presence of RIDNs in Tg-RTN3 mice correlated with significant impairments in spatial learning, memory, and synaptic plasticity.

Conclusions:

• RTN3 aggregation is a significant contributor to neuritic dystrophy in Alzheimer's disease (AD) pathogenesis.
• RIDNs induced by RTN3 aggregation may play a crucial role in the cognitive dysfunction observed in AD.
• Inhibiting RTN3 aggregation presents a promising therapeutic avenue for mitigating neuritic dystrophy and potentially treating AD.